John Tsai
Director/Board Member en BLUEPRINT MEDICINES CORPORATION .
Fortuna: 2 M $ al 31/03/2024
Perfil
En la actualidad, John Tsai es Director Médico de Novartis AG. En su anterior carrera, el Dr. Tsai fue Director Médico y Vicepresidente Senior de Medicina Global en Amgen, Inc. y Jefe de Desarrollo Clínico en Bristol Myers Squibb Co. Se doctoró en la Facultad de Medicina de la Universidad de Louisville y se licenció en la Universidad de Washington en San Luis.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
NOVARTIS AG
0.00% | 31/12/2022 | 13 550 ( 0.00% ) | 1 M $ | 31/03/2024 |
| 21/06/2023 | 6 500 ( 0.01% ) | 616 590 $ | 31/03/2024 |
Cargos activos de John Tsai
| Empresas | Cargo | Inicio |
|---|---|---|
| BLUEPRINT MEDICINES CORPORATION | Director/Board Member | 06/01/2023 |
Syncona Partners LLP
 Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | Private Equity Investor | - |
| Forcefield Therapeutics Ltd. | Chief Executive Officer | 27/09/2023 |
SwanBio Therapeutics, Inc.
 SwanBio Therapeutics, Inc. BiotechnologyHealth Technology SwanBio Therapeutics, Inc. operates as a gene therapy firm. The company was founded by Tom Anderson, Rachel Salzman, Karen Kozarsky and Florian S. Eichler and is headquartered in Bala Cynwyd, PA. | Chairman | 16/10/2023 |
Antiguos cargos conocidos de John Tsai.
| Empresas | Cargo | Fin |
|---|---|---|
| NOVARTIS AG | Chief Tech/Sci/R&D Officer | 15/05/2022 |
| AMGEN INC. | Chief Tech/Sci/R&D Officer | 01/01/2018 |
| BRISTOL-MYERS SQUIBB COMPANY | Private Equity Investor | 01/01/2012 |
Novartis Institute for Functional Genomics, Inc.
 Novartis Institute for Functional Genomics, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institute For Functional Genomics, Inc. serves as a bridge between basic science and preclinical drug discovery for Novartis’ global research organization. Its focus areas include oncology, autoimmunity, cardiovascular disease, diabetes, musculoskeletal disorders, and infectious disease. The company was founded in 1999 and is headquartered in San Diego, CA. | Director/Board Member | - |
Formación de John Tsai.
| Washington University in St. Louis | Undergraduate Degree |
| University of Louisville School of Medicine | Doctorate Degree |
Experiencias
Funciones ocupadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 4 |
|---|---|
| AMGEN INC. | Health Technology |
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| NOVARTIS AG | Health Technology |
| BLUEPRINT MEDICINES CORPORATION | Health Technology |
| Empresas privadas | 4 |
|---|---|
Novartis Institute for Functional Genomics, Inc.
Novartis Institute for Functional Genomics, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institute For Functional Genomics, Inc. serves as a bridge between basic science and preclinical drug discovery for Novartis’ global research organization. Its focus areas include oncology, autoimmunity, cardiovascular disease, diabetes, musculoskeletal disorders, and infectious disease. The company was founded in 1999 and is headquartered in San Diego, CA. | Commercial Services |
Syncona Partners LLP
Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | Finance |
SwanBio Therapeutics, Inc.
SwanBio Therapeutics, Inc. BiotechnologyHealth Technology SwanBio Therapeutics, Inc. operates as a gene therapy firm. The company was founded by Tom Anderson, Rachel Salzman, Karen Kozarsky and Florian S. Eichler and is headquartered in Bala Cynwyd, PA. | Health Technology |
| Forcefield Therapeutics Ltd. |
- Bolsa de valores
- Insiders
- John Tsai
